Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

NeuroSense Therapeutics (NRSN)

NeuroSense Therapeutics Ltd
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:NRSN
DateTimeSourceHeadlineSymbolCompany
07/05/202413:45PR Newswire (US)NeuroSense Announces New Positive Data Analysis from PARADIGM Clinical Trial Demonstrating Statistically Significant Slowing of Disease Progression in High-Risk ALS PatientsNASDAQ:NRSNNeuroSense Therapeutics Ltd
02/05/202414:19PR Newswire (US)NeuroSense Announces First Quarter 2024 Business UpdateNASDAQ:NRSNNeuroSense Therapeutics Ltd
22/04/202413:30PR Newswire (US)NeuroSense and Genetika+ Initiate Precision Medicine Collaboration Beginning with Ongoing Phase 2 Clinical Trial in Alzheimer's DiseaseNASDAQ:NRSNNeuroSense Therapeutics Ltd
18/04/202413:30PR Newswire (US)NeuroSense Presents Positive Data Validating Phase 2b Topline Readout During Emerging Science Presentation at the American Academy of Neurology Annual MeetingNASDAQ:NRSNNeuroSense Therapeutics Ltd
12/04/202413:30PR Newswire (US)NeuroSense to Present PARADIGM Data at the American Academy of Neurology Annual Meeting April 16, 2024NASDAQ:NRSNNeuroSense Therapeutics Ltd
11/04/202400:16PR Newswire (US)NeuroSense Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private PlacementNASDAQ:NRSNNeuroSense Therapeutics Ltd
09/04/202413:30PR Newswire (US)NeuroSense Collaborates with Lonza to Identify Exosome-based Biomarkers, in order to Advance Neurodegenerative Disease Treatments and DiagnosticsNASDAQ:NRSNNeuroSense Therapeutics Ltd
05/04/202414:29PR Newswire (US)NeuroSense Announces Year End 2023 Financial Results and Provides Business UpdateNASDAQ:NRSNNeuroSense Therapeutics Ltd
22/02/202413:25Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:NRSNNeuroSense Therapeutics Ltd
22/02/202413:25Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:NRSNNeuroSense Therapeutics Ltd
21/02/202413:30PR Newswire (US)NeuroSense Reports Additional Positive Results from its ALS Phase 2b PARADIGM TrialNASDAQ:NRSNNeuroSense Therapeutics Ltd
13/02/202418:20Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:NRSNNeuroSense Therapeutics Ltd
13/02/202415:14Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:NRSNNeuroSense Therapeutics Ltd
07/02/202414:38Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:NRSNNeuroSense Therapeutics Ltd
07/02/202414:27PR Newswire (US)NeuroSense Regains Compliance with NASDAQ Minimum Bid Price RuleNASDAQ:NRSNNeuroSense Therapeutics Ltd
09/01/202413:49Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:NRSNNeuroSense Therapeutics Ltd
09/01/202413:48Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:NRSNNeuroSense Therapeutics Ltd
09/01/202413:45PR Newswire (US)NeuroSense Recaps Positive 2023 Achievements Including Statistically Significant Slowing of Disease Progression in Phase 2b ALS Trial of PrimeC and Highlights Anticipated 2024 CatalystsNASDAQ:NRSNNeuroSense Therapeutics Ltd
27/12/202322:03Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:NRSNNeuroSense Therapeutics Ltd
27/12/202322:01Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:NRSNNeuroSense Therapeutics Ltd
27/12/202322:00PR Newswire (US)NeuroSense Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity RequirementNASDAQ:NRSNNeuroSense Therapeutics Ltd
21/12/202313:45Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:NRSNNeuroSense Therapeutics Ltd
14/12/202321:30Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:NRSNNeuroSense Therapeutics Ltd
14/12/202314:41Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:NRSNNeuroSense Therapeutics Ltd
14/12/202314:24PR Newswire (US)NeuroSense Reports New Data: Statistically Significant Clinical Efficacy in Phase 2b ALS TrialNASDAQ:NRSNNeuroSense Therapeutics Ltd
05/12/202320:15Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:NRSNNeuroSense Therapeutics Ltd
05/12/202320:00Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:NRSNNeuroSense Therapeutics Ltd
05/12/202313:01Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:NRSNNeuroSense Therapeutics Ltd
05/12/202313:00PR Newswire (US)NeuroSense's Phase 2b ALS Trial Achieves Primary Safety and Tolerability & Secondary Clinical Efficacy EndpointsNASDAQ:NRSNNeuroSense Therapeutics Ltd
05/12/202305:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:NRSNNeuroSense Therapeutics Ltd
 Showing the most relevant articles for your search:NASDAQ:NRSN